Can new drugs stop GLP-1 weight loss from costing you muscle?

GLP-1 receptor agonists have transformed obesity and type 2 diabetes treatment, but body composition data raise a concern. Across major trials, fat-free mass accounted for roughly 45% of weight lost with semaglutide 2.4 mg (STEP-1), 40% with semaglutide 1.0 mg (SUSTAIN-8), 25% with tirzepatide (SURMOUNT-1) and 15% with liraglutide. Natural age-related muscle loss runs about 0.6-1% per year, so the authors argue that lean mass lost on these drugs over 6-12 months could equal decades of aging, which is especially worrying for older adults and people with sarcopenic obesity.

The picture is not uniform. A meta-analysis found fat-free mass loss comparable to lifestyle-based weight loss, one study saw a 14.9% increase in fat-free mass when exercise was added, and genetic proxies of lifelong GLP-1 receptor activation tracked with fat loss rather than lean loss. Fat-free mass also includes organs, water and bone, and skeletal muscle is rarely measured directly. In mice, semaglutide cut fast-twitch muscle force about 20% despite minimal atrophy, suggesting muscle quality can decline even when size does not. Weight regain after stopping may be mostly fat, worsening the fat-to-lean ratio over repeated cycles.

This narrative review, searched in March-April 2025 across PubMed, JAMA, Wiley, ResearchGate and ClinicalTrials.gov, examined nine candidate compounds. It prioritized DXA or MRI body composition and functional measures such as grip strength and stair climb. The lead candidate is bimagrumab, an antibody blocking activin receptor type IIB, which myostatin and activin A use to suppress muscle growth. In a randomized, placebo-controlled phase 2 trial in adults with type 2 diabetes and BMI 28-40, bimagrumab 10 mg/kg every 4 weeks for 48 weeks produced 6.5% weight loss, a 20.5% fat mass reduction (versus 0.5% with placebo) and a 3.6% lean mass gain (versus a 0.8% loss). Insulin sensitivity rose about 20%.

Caveats applied even here: grip strength did not improve, DXA cannot rule out water contributing to the lean gain, and 84% of participants took metformin. Combination data are more relevant. In diet-induced obese mice, semaglutide lowered lean mass 10%, bimagrumab raised it 8%, and the pair fully preserved lean mass while cutting fat mass 70%. In the 48-week phase 2b BELIEVE trial, the high-dose combination produced about 20% weight loss (24.2 kg) versus 14.8% with semaglutide alone. Lean mass fell 2.6% with the combination versus 7.9% with semaglutide, and fat made up 92.8% of weight lost. The review's text and table report slightly different BELIEVE percentages.

Safety looked acceptable but incompletely characterized. Common bimagrumab effects were diarrhea, muscle spasms and acne, with reversible creatine kinase elevations and a reversible FSH decrease whose fertility implications are unknown. Per the abstract, similar lean-mass benefits were seen with trevogrumab, garetosmab, apitegromab and SRK-439, and the selective androgen receptor modulator enobosarm also improved physical function. The supplied text cuts off before these sections, so details are limited. Several bimagrumab-tirzepatide trials are now recruiting.

The authors conclude that pharmacological muscle preservation is promising but unproven. None of these agents is approved alongside weight loss drugs, long-term safety is unknown, and functional benefit has yet to be demonstrated consistently. Until larger controlled trials report, resistance training and adequate protein remain the evidence-based way to protect muscle during GLP-1 therapy.